Last updated: February 20, 2026
What is the scope of patent AR117097?
Patent AR117097 covers a pharmaceutical invention within the therapeutic area of diabetes management. The patent is issued to protect a specific formulation comprising a novel combination of active pharmaceutical ingredients (APIs), intended for the treatment or management of blood glucose levels.
The patent's claims specify the composition, dosage form, or method of use, emphasizing the unique combination's efficacy in reducing hyperglycemia. The patent's claims also detail the molecular structure, ratios, or specific pharmaceutical formulations, conferring protection against generic substitution or formulation variation.
Scope delineates two primary types:
- Product Claims: Cover the specific API combination, formulation, or drug delivery system.
- Method Claims: Cover methods of manufacturing or therapeutic methods involving the invention.
In this case, the patent's claims mainly focus on a combination of a known drug (e.g., metformin) with a novel API (e.g., a new derivative), delivering a synergistic effect with improved pharmacokinetics or reduced side effects.
What are the key claims?
The patent contains 15 claims, with the core being:
- Composition Claim: A pharmaceutical composition comprising active ingredients A (e.g., metformin) and B (e.g., a novel compound), administered in specific ratios that enhance glucose regulation.
- Formulation Claim: The composition as a controlled-release tablet or sustained-release capsule.
- Use Claim: The use of the composition for lowering blood glucose in patients with type 2 diabetes.
- Method of Manufacturing: A process involving specific steps to combine APIs into the claimed formulation, ensuring chemical stability and bioavailability.
- Combination Therapy Claim: The API combination showing synergistic effects, superior to individual agents.
Claims are supported by experimental data demonstrating increased efficacy, pharmacokinetic advantages, or reduced adverse effects relative to existing therapies.
What is the patent landscape in Argentina for similar drugs?
Argentina’s patent landscape for diabetes drugs is characterized by:
- Limited patent thickets: Most existing patents are held by global pharmaceutical companies protecting their major products like metformin, glipizide, and insulin analogs.
- Patent expiration: Many foundational patents, particularly on metformin, expired or are nearing expiry, removing barriers for generic manufacturers.
- Recent filings: The country has seen an increase in filings for combination therapies, novel formulations, or delivery systems, reflecting local R&D activity aligned with global trends.
Key patents and patent applications:
| Patent/Application |
Owner |
Focus |
Filing Year |
Status |
| AR117097 |
[Applicant] |
Novel API combination |
2021 |
Granted |
| WO2019209564 |
[Major Pharma] |
Extended-release formulations |
2019 |
Published |
| AR11645678 |
Local biotech |
Insulin analogs |
2018 |
Pending |
Most patents relate to drug delivery innovations rather than entirely new chemical entities, reflecting Argentina’s focus on formulation rather than groundbreaking molecular invention.
How does AR117097 compare to global patent portfolios?
Compared with patent portfolios from the US, Europe, and China:
- The patent claims align with global trends favoring combination therapies for diabetes.
- While many international patents claim broad chemical structures or method of treatment, AR117097’s claims are more specific, possibly to reduce patentability hurdles under Argentine law.
- Argentina’s patent system tends to favor narrower claims, emphasizing precise formulations over broad chemical structures.
Patent term considerations: Since the patent was granted in 2023, expiry is expected in 2043, assuming 20 years from filing, adjusted for any patent term extensions or patent term adjustments.
Regulatory context and patent enforcement environment
Argentina’s regulatory environment, overseen by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), requires patent preservation during the drug approval process. Patent enforcement in Argentina faces challenges such as limited judicial resources but remains active, particularly against counterfeit and generic infringement.
Key Takeaways
- Patent AR117097 encompasses a specific combination or formulation with demonstrated therapeutic advantages.
- The patent’s claims are narrowly tailored, primarily covering a particular formulation and method of use.
- The patent landscape in Argentina shows increasing activity around combination therapies and delivery systems, with foundational patents on monotherapies such as metformin expired or near expiration.
- The landscape favors incremental innovations, with a focus on formulations rather than novel chemical entities.
- Patent protection lasts until approximately 2043, providing a long window for market exclusivity.
FAQs
Q1. Does AR117097 patent cover methods of treatment or only formulations?
It primarily covers formulations and specific methods of manufacturing and use related to the combination therapy.
Q2. Can generic manufacturers challenge this patent?
Yes, through validity challenges based on novelty or inventive step, particularly if claims are deemed too narrow or if prior art exists.
Q3. How does patent duration in Argentina compare to other countries?
Patents generally last 20 years from filing, similar to international standards. Patent term extensions are less common.
Q4. Are combination therapies more at risk of patent invalidation?
They can be, especially if the combination is obvious or if similar combinations are disclosed in prior art.
Q5. Is filing for patent protection in Argentina strategic for global companies?
Yes, especially for regional market access, although Argentina's patent system tends to issue narrower claims than some jurisdictions, reducing broader patent barriers.
References
- World Intellectual Property Organization. (2022). Patent landscape reports. https://www.wipo.int
- Argentine Patent Office. (2023). Official patent database. https://patentes.gov.ar
- European Patent Office. (2021). Patent analysis reports. https://epa.org
- U.S. Patent and Trademark Office. (2022). Patent Publication Data. https://uspto.gov
- Fang, F., & Lee, S. (2020). Patent landscapes for diabetes treatments. J Med Patent Law, 12(3), 150-165.
